This Dividend King Has Raised Its Payout for More Than 60 Straight Years. But Is the Stock Still a Buy?

Johnson & Johnson raised its quarterly dividend 3.1% to $1.34/share ($5.36 annual) for the 64th consecutive year, implying a ~2.1% yield and covering ~46% of expected 2026 non-GAAP earnings (~$11.55 adjusted EPS guidance). While talc litigation remains an overhang (tens of thousands of claims; $10B settlement rejected), management highlighted resilience as total revenue rose 9.9% to $24.1B and cancer drugs Darzalex and Tremfya grew ~22% and ~68%, respectively. After a >60% run over the past year and trading near ~$257 at ~22x guidance, the article frames JNJ as a high-quality long-term dividend compounder but suggests waiting for a pullback given the premium valuation.

Analysis

JNJ is now being valued like a defensive compounder rather than a litigation-discount story, which changes the payoff. Once the discount is gone, incremental upside depends on revenue mix sustaining itself faster than consensus expects; if the newer immunology/oncology assets merely offset legacy erosion, the stock can sit on a high multiple without re-rating further. The market is also underpricing how much of the “safe dividend” appeal is already embedded in the share price, leaving less room for total-return surprises.

The near-term risk is not the payout, it is multiple compression from any evidence that the post-Stelara growth bridge is less durable than management implies. The most important tell over the next 1-3 quarters is whether newer drugs can preserve operating leverage after pricing, rebates, and launch spend; if they cannot, the market will treat the portfolio as a low-growth, litigation-litigated bond proxy and shave 2-3 turns off the multiple quickly. A bad talc headline remains a tail-risk catalyst, but the bigger downside is a boring earnings miss: that is what can reset expectations in a premium-valued defensive name.

Contrarian take: the consensus is focused on dividend safety when the real issue is opportunity cost. In a market where quality growth still commands a premium, owning JNJ here is a duration bet with limited rerating potential and no obvious catalyst for a higher multiple. The strongest second-order effect is rotational: if healthcare buyers want safety plus growth, capital is more likely to drift toward names with cleaner growth runways and less legal noise, while JNJ becomes a source of funds on strength rather than a new-core accumulation idea.

Key Decisions for Investors

• Do not initiate fresh JNJ longs at current levels; wait for a 5-8% pullback or a quarter where non-Stelara growth re-accelerates enough to justify the 22x multiple. Upside from here looks mid-single-digit at best without a new catalyst.
• For existing JNJ holders, consider overwriting with 1-2 month covered calls 3-5% above spot to monetize the premium valuation; this is a better risk/reward than adding outright equity here.
• Relative-value idea: pair long MSFT / short JNJ for investors seeking AAA balance-sheet exposure plus better secular growth. Thesis fails if JNJ’s pipeline keeps beating while MSFT multiple de-rates on AI capex concerns.
• Set an alert for any talc-related court/settlement headline or guidance downgrade; either can trigger a 10-15% de-rating even if the dividend remains untouched.